Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.50 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KRAS | P01116 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3011502 | 1.00 | MAOB (0.58) | MAOBBCHEMAPTALDH1A1LMNA | |
| SCHEMBL3012126 | 0.80 | CYP1B1 (0.56) | MAOBBCHEMAPTALDH1A1LMNA | |
| SCHEMBL3012123 | 0.80 | CYP1B1 (0.56) | MAOBBCHEMAPTALDH1A1LMNA | |
| SCHEMBL6733848 | 0.75 | MAOB (0.85) | MAOBBCHEMAPTALDH1A1LMNA | |
| SCHEMBL6733854 | 0.75 | MAOB (0.85) | MAOBBCHEMAPTALDH1A1LMNA | |
| SCHEMBL29903249 | 0.74 | RAB9A (0.62) | MAOBMAPTALDH1A1LMNAMEN1 | |
| SCHEMBL29870504 | 0.74 | MAPT (0.68) | MAOBBCHEMAPTALDH1A1LMNA | |
| SCHEMBL6791116 | 0.74 | MAPT (0.68) | MAOBBCHEMAPTALDH1A1LMNA | |
| SCHEMBL6791109 | 0.74 | MAPT (0.68) | MAOBBCHEMAPTALDH1A1LMNA | |
| SCHEMBL11803175 | 0.74 | MAOB (1.00) | MAOBBCHEMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9162991-B2 | Cinnamoyl inhibitors of transglutaminase | UNIVERSITY OF OTTAWA (CA) | 2015-10-20 | — | — | US | disclosed |
| US-20140024837-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | UNIVERSITE DE MONTREAL (CA) | 2014-01-23 | — | — | US | disclosed |
| US-8614233-B2 | Cinnamoyl inhibitors of transglutaminase | UNIVERSITE DE MONTREAL (CA) | 2013-12-24 | — | — | US | disclosed |
| US-20100204280-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | UNIVERSITE DE MONTREAL (CA) | 2010-08-12 | — | — | US | disclosed |
| WO-2008144933-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | Université de Montréal (CA) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204280-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | TGM2, TGM3, TGM1 | MAOB 1977/4885BCHE 1144/4885MAPT 1920/4885 |
| US-20140024837-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | TGM2, TGM3, TFPI | MAOB 2187/4885BCHE 1509/4885MAPT 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.